Eli Lilly weight-loss drug data causes drop in sleep apnea treatment stocks
Results from a new clinical trial for Eli Lilly‘s obesity medicine have caused a significant upset for the sleep apnea treatment industry. Shares of ResMed, a firm that sells continuous positive airway pressure machines that treat moderate to severe sleep apnea,